To learn more about any studies, please contact Armando Ramirez, Senior Research Coordinator, at Armando_ramirez@bchphysicians.org, or 914-504-0152

STUDY (click for full study details) *BRIEF STUDY DESCRIPTION*	**BRIEF PARTICIPANT CRITERIA**
Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Health Participants and Participants with CF *New mRNA Therapy for CF*	• 18-60 years old • FEV1 50%-100% • Not genetically eligible for or not taking modulators (exclusions apply)
Phase 1 Study of Inhaled KB407, a Replication-Defective, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator, for the Treatment of CF *New inhaled CFTR (HSV-1)-derived vector for CF*	• ≥18 years old • FEV1 50%-100% • Not genetically eligible for modulators
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study (STOP360AG) *One IV Antibiotic v. Two IV Antibiotics for treatment of Pulmonary Exacerbation with Pseudomonas*	• ≥6 years old • Needing treatment for a CF pulmonary exacerbation with IV antibiotics
Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF (STRONG-CF) *Observational Study For People With CF*	• ≥18 years old • FEV1 ≤70%
Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators (REACH) *Observational Study For People With CF Not Taking Modulators*	• ≥18 years old • Not currently taking modulators
Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult CF Subjects With Chronic Pseudomonas Aeruginosa (PsA) Pulmonary Infection *Nebulized phage for adults with CF with chronic pseudomonas aeruginosa*	• ≥18 years old • FEV1 40%-80% • Positive for pseudomonas aeruginosa in the last 12 months
Phase 2a Randomized, Double-blind, Placebo-controlled Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Physician-prescribed Trikafta® in People With CF Who Are Homozygous for F508del Mutation New Add-On Therapy for People with CF Taking Trikafta®	• ≥18 years old • F508del homozygous • FEV1 40%-100% • Currently taking Trikafta
Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY® Study) New Medicine for both CF and Non-CF Bronchiectasis	• ≥18 years old • Confirmed bronchiectasis • At least one pulmonary exacerbations requiring antibiotics in last 12 months
Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With CF New Modulator for CF	• ≥18 years old • Heterozygous F508del with second variant non-responsive to Trikafta • FEV1 ≥40%